Bay Area Team Against Resistance







PI: Trever Bivona MD PhD Sourav Bandyopadhyay PhD Jonathan Weissman PhD (HHMI) Kevan Shokat PhD (HHMI) Collin Blakely MD PhD Eric Collisson MD Co-PI: Calvin Kuo MD PhD Ron Levy MD Heather Wakelee MD Suki Padda, MD

Unleashing the full potential of molecular medicine

<u>Targeted therapy</u> is effective:




• Almost all tumors develop resistance:




High burden and mortality of lung cancer

- 1 in 15 Americans will be diagnosed with lung cancer
- •65% of lung cancer diagnoses are in non-smokers
- Lung cancer kills more people than the next 3 deadliest cancers combined
 - Lung cancer kills 3X as many men as prostate cancer
 - Lung cancer 2X as many women as breast cancer
- Only \$1,680 is spent on federal research per life lost from lung cancer; \$25,118 is spent in breast cancer; \$12,644 in prostate cancer

Paradigm-defining molecular landscape of lung adenocarcinoma




Precision oncology: promise & challenge




Bivona and Doebele 2016

Systematic study of human specimens



Bay Area Team Against Resistance



Bay Area Team Against Resistance

Systematic Collection of Lung Cancer On-Treatment Core Biopsies

<u>Project 1</u> Tyrosine Kinase Inhibitor Resistance

> EGFR TKI ALK TKI


Leads: Bivona, Bandyopadhyay UCSF

Molecular profiling Single cell analysis Organoid development PDX models Computational modeling Small molecule/CRISPR screens

UCCE

Project 2 Immunotherapy Resistance anti PD-1 (pembrolizumab, nivolumab) Leads: Kuo, Levy

Characterizing and targeting the tumor ecosystem



Bivona TG Nature Medicine 2016

Thank you!





PI: Trever Bivona MD PhD Sourav Bandyopadhyay PhD Jonathan Weissman PhD (HHMI) Kevan Shokat PhD (HHMI) Collin Blakely MD PhD Eric Collisson MD Co-PI: Calvin Kuo MD PhD Ron Levy MD Heather Wakelee MD Suki Padda, MD